AdAlta IPF Program featured in Small Caps

Small Caps, a site dedicated to market news & information on ASX listed small cap companies, recently published a great feature detailing AdAlta’s recent manufacturing announcement along with background on AdAlta’s i-body technology and lead candidate, AD-214 for Idiopathic Pulmonary Fibrosis. The article, titled ‘AdAlta courts big pharma with ‘enhanced’ anti-fibrosis drug, locks-in manufacturing agreements‘ can be accessed here.